

PREDICTIVE TECHNOLOGY GROUP, INC.

Consolidated Balance Sheet

For the period ending March 31, 2017

(Unaudited)

Assets

Current Assets

| | |
|---|------------------|
| Cash | \$ 94,714 |
| Accounts Receivable | 29,615 |
| Inventory | 75,758 |
| Subscriptions Receivable | - |
| Notes Receivable from Juneau Bioscience | 3,295,694 |
| Prepaid Expenses | 25,500 |
| Total Current Assets | <u>3,521,282</u> |

| | |
|--------------------------------------|-------|
| Office Equipment net of depreciation | 9,981 |
|--------------------------------------|-------|

| | |
|--------------------|-----------|
| License Agreements | 1,660,560 |
|--------------------|-----------|

| | |
|---------|-----------|
| Patents | 8,129,745 |
|---------|-----------|

| | |
|----------------------------|------------|
| Investment in Subsidiaries | 32,935,485 |
|----------------------------|------------|

| | |
|--------------|-----------------------------|
| Total Assets | <u><u>\$ 46,257,053</u></u> |
|--------------|-----------------------------|

Current Liabilities

| | |
|--|------------|
| Accounts Payable and Accrued Liabilities | \$ 210,963 |
|--|------------|

| | |
|---------------------------|----------------|
| Total Current Liabilities | <u>210,963</u> |
|---------------------------|----------------|

Equity

| | |
|---|---------|
| Common Stock, Par Value .001, 182,884,682 shares issued and outstanding, 900,000,000 Shares Authorized | 182,885 |
|---|---------|

| | |
|-----------------|------------|
| Paid in Capital | 48,782,393 |
|-----------------|------------|

| | |
|-------------------|--------------------|
| Retained Earnings | <u>(2,919,188)</u> |
|-------------------|--------------------|

| | |
|------------------------------|-----------------------------|
| Total Liabilities and Equity | <u><u>\$ 46,257,053</u></u> |
|------------------------------|-----------------------------|

See accompanying notes to financial statements

PREDICTIVE TECHNOLOGY GROUP, INC.

Consolidated Income Statement

For the Three and Nine Months Ended March 31 2017

(Unaudited)

| | Three Months Ended March 31, 2017 | Nine Months Ended March 31, 2017 |
|------------------------------------|---|--|
| Ordinary Income/Expense | | |
| Revenue | \$ 597,666 | \$ 699,920 |
| Cost of Goods Sold | 228,172 | 342,115 |
| Net Sales | 369,494 | 357,805 |
| Administrative and Selling Expense | 333,245 | 621,398 |
| Research and Development | 26,541 | 33,041 |
| Net Income before other income | 9,707 | (296,634) |
| Accrued Interest Income | 96,926 | 252,175 |
| Net Income | \$ 106,633 | \$ (44,459) |

See accompanying notes to financial statements

PREDICTIVE TECHNOLOGY GROUP, INC.
Consolidated Statement of Cash Flows (Indirect Method)
For the Three and Nine Months Ended March 31 2017
(Unaudited)

| | Three Months Ended March 31, 2017 | Nine Months Ended March 31, 2017 |
|--|---|--|
| Cash Flows from Operating Activities | | |
| Net income | \$ 106,633 | \$ (44,459) |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | | |
| Depreciation and amortization | 1,222 | 2,063 |
| Accrued Interest Income | (96,926) | (252,175) |
| Loss in Juneau | - | 58,869 |
| (Increase) decrease in Accounts Receivable | (5,065) | 42,385 |
| (Increase) decrease in Inventory | (2,551) | (75,758) |
| (Increase) decrease in Prepaid Expenses | (7,500) | (25,500) |
| Increase (decrease) in Accounts Payable | 134,759 | 198,496 |
| Net cash provided (used) by operating activities | <u>130,572</u> | <u>(96,079)</u> |
| Cash Flows from Investing Activities | | |
| Capital expenditures | (10,625) | (12,394) |
| License Payments | <u>(308,000)</u> | <u>(1,115,560)</u> |
| Net cash provided (used) by investing activities | <u>(318,625)</u> | <u>(1,127,954)</u> |
| Cash Flows from Financing Activities | | |
| Contributions of Capital | <u>207,500</u> | <u>1,315,100</u> |
| Net cash provided (used) by financing activities | <u>207,500</u> | <u>1,315,100</u> |
| Net increase (decrease) in Cash | 19,446 | 91,067 |
| Cash at beginning of prior period | <u>75,268</u> | <u>3,647</u> |
| Cash at end of period | <u>\$ 94,714</u> | <u>\$ 94,714</u> |

See accompanying notes to financial statements

PREDICTIVE TECHNOLOGY GROUP, INC.

Notes to Consolidated Financial Statements

For the Quarter Ending March 31, 2017

NOTE 1 The Company

These consolidated financial statements include the accounts of Predictive Technology Group, Inc and the operating results of its wholly owned subsidiaries: Predictive Therapeutics, LLC, Predictive Biotech, Inc. and LifeCode Genetics, Inc.

Predictive Technology Group, Inc. (the Company) through its wholly owned subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/Human Cells, Tissues and Human Cellular and Tissue-Based Products (HCT/Ps). The Company uses this information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and pharmaceutical therapeutics and HCT/Ps designed to effectively prevent and treat the disease.

Predictive Therapeutics, LLC seeks to revolutionize the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression and has acquired and/or licensed intellectual property related to endometriosis, scoliosis, and degenerative disc disease (deformities of the spine).

Predictive Biotech, Inc. was acquired in April 2016 and seeks to provide physicians with high quality human cell and tissue products (HCT/Ps) and is the early stages of developing distributor relationships and production.

LifeCode Genetics, Inc. owns an 11.885% interest in Juneau Biosciences, LLC. Juneau conducts research into the diagnosis and treatment of common women's health conditions, such as endometriosis. Some of the diagnostic technologies to be commercialized by the Company and its subsidiaries are licensed from Juneau.

NOTE 2 Summary of Significant Accounting Policies

This summary of significant accounting policies of the Company is presented to assist in understanding the financial statements. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of these financial statements.

Year End. The board of directors of Predictive Technology Group has elected to change its year end from August 31 to June 30. Accordingly, these financial statements represent the result of operations for the three months ended March 31, 2017 (third quarter and year to date for the fiscal year beginning July 1, 2016).

Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents. Predictive Technology Group, Inc. considers all highly liquid investments purchased with an original maturity of twelve months or less to be cash equivalents.

Inventories. Inventories consist primarily of human cell and tissue products (HCT/Ps) produced by Predictive Biotech, Inc. using direct costs assuming a standard cost of production. Predictive Biotech is in the early production stage of manufacturing. All other costs, including administrative costs are expensed as incurred.

Stock Subscriptions Receivable. Stock Subscriptions are recorded as a receivable on the day the subscription agreement is signed and accepted by the Company. At the date of these financial statements, all subscriptions have been collected.

Prepaid Rents. Amounts paid in advance for rents are accounted for as prepaid rents and classified as current assets if such amounts are to be recognized as expense with the current period.

Patents. The Company capitalizes the legal costs of obtaining patents and amortizes such costs over the life of the patent, once the technologies covered by the patent are commercialized.

Revenue Recognition. Revenue is recognized when products are shipped. The Company generally requires payment at the time of sale.

Intercompany Accounts and Transactions. All significant intercompany accounts and transactions have been eliminated in these consolidated financial statements.

Income Taxes. Deferred tax assets and liabilities are recorded to reflect the future tax consequences attributable to the effects of differences between the carrying amounts of existing assets and liabilities for financial reporting and for income tax purposes. Deferred taxes are calculated by applying enacted statutory tax rates and tax laws to future years in which temporary differences are expected to reverse. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate change is enacted. As of March 31, 2017, no allowance is required.

NOTE 3 NOTES RECEIVABLE FROM JUNEAU BIOSCIENCE

On August 1, 2016, the company entered into agreements to acquire convertible, unsecured notes receivable from Juneau Biosciences, LLC from three separate entities, in exchange for stock of the Company. The notes bear interest at 12% and are convertible into Class A Units of Juneau at the rate of \$1.00 per unit. Of the three notes acquired, \$2,239,919 is due on demand, with the balance of the notes due August 1, 2017.

NOTE 4 INTELLECTUAL PROPERTY & LICENSE AGREEMENTS

Predictive Technology Group, Inc. through its acquisitions of Predictive Therapeutics, LLC has a number of patents and license agreements categorized under “Intellectual Property” and “Licenses Agreements.”

License Agreements with Juneau Bioscience

On July 9, 2015, Predictive Therapeutics signed a license agreement for the commercialization of assays and related services for the prognosis and monitoring of endometriosis, and other health concerns, in the infertility market. This agreement called for license payments of \$1,300,000 during the first six months of the agreement. Accordingly, the license was initially recorded by a charge to the asset and a corresponding credit to a current liability in the amount of the required license payments. The Company paid \$250,000 prior to amending the agreement and the August 31, 2015 financial statement has been restated as described below.

On December 28, 2016, Predictive Therapeutics and Juneau Biosciences amended and restated the license agreement dated July 9, 2015. The assay is in the late stage of development. The amended license fees associated with this agreement require minimum monthly payments of \$105,000 through April 2017, Beginning in May 2017, minimum monthly payments of \$120,000 through August 2017, and subsequent payments of \$500,000 for the next four consecutive months.

Additionally, prior to June 23, 2017 Predictive will loan \$1,000,000 to Juneau on terms similar to current outstanding loans made by Juneau to Predictive. The term will be two years and the interest rate will be 8% with interest and principal due upon the two-year anniversary of the note origination date.

An additional license fee of \$2,000,000 is due and payable once the Company has received profits of \$25,000,000 under the agreement.

Upon first commercial sale of the of licensed assay, the Company will issue Juneau common shares with a market value of \$2,500,000. Net sales, once commercially available, are split evenly by the Company and Juneau after deducting the cost of the lab test fee, subject to certain minimums.

The Company has elected to capitalize the periodic payments when paid, through the development stage and will begin to amortize the licenses once the products are commercially available.

The following table outlines the patents covered by this license agreement:

| Title | Ser #, Patent # or Pub # | | 1st Named Inventor | Status |
|---|---------------------------------|----|---------------------------|---------------|
| Genetic Markers Associated with Endometriosis and Use Thereof | 12/765,643 US 2010/0272713 | US | Kenneth Ward | Pending |
| Genetic Markers Associated with Endometriosis and Use Thereof | 13/159,132 US 2015/0361494 | US | Kenneth Ward | Pending |
| Method of Determining Predisposition of Endometriosis | 13/603,284 US 2015/0363558 | US | Kenneth Ward | Pending |
| Method of Determining Predisposition of Endometriosis | 13/788,913 US 8,932,993 | US | Kenneth Ward | Issued |
| Method of Testing for Endometriosis and Treatment Thereof | 13/789,082 US 2015/0368714 | US | Kenneth Ward | Pending |
| Method of Testing for Endometriosis and Treatment Thereof | 14/594,266 US 2015/0133382 | US | Kenneth Ward | Pending |
| Additional US and International filings in process | | | | |

In addition to the license for the commercialization of assays and related services for the prognosis and monitoring of endometriosis in the infertility market, the company has entered into a license agreement with Juneau to use the assay as a companion diagnostic test as the rationale for on-label endometriosis therapeutic patents. This license agreement was amended and restated on August 1, 2016 and amends the previous agreement dated August 16, 2013.

The agreement initially required a \$250,000 license fee which was paid during 2013 and 2014. A subsequent milestone payment of 250,000 shares of Company stock was due to Juneau on October 19, 2016 and which have been issued. An additional milestone payment of \$250,000 is due September 1, 2017. Once FDA approval has been granted on any companion diagnostic test, a final milestone payment of \$250,000 is due.

The agreement requires a 2% royalty for the sale of patented therapeutic products specifically covered by the agreement.

The Company owns the following therapeutic and method of use patents and have no contingency or royalty obligations (except as described above):

| Ser #, Patent # Pub | 1st Name Inventor | | Status | |
|--|-------------------------------------|----|---------------------|-----------------------|
| Progestin Cannabis Therapeutic and Method of Use | 14/281,172 US 9,149,499 | US | Bradley C. Robinson | Issued |
| Progestin NSAID Therapeutic and Method of Use | 14/281,127 US 9,161,941 | US | Bradley C. Robinson | Issued |
| Progestin NSAID Therapeutic and Method of Use | PCTUS2014386018 | US | Bradley C. Robinson | National Filing Stage |
| Progestin NSAID Therapeutic and Method of Use | 14/875,656 US 2016/0022696 | US | Bradley C. Robinson | Pending |
| Method of Treating Endometriosis | 62/275,413 | US | Bradley C. Robinson | Pending |

Additional US and International filings in process

Other Patents and Technologies

The following patents were acquired by Predictive Therapeutics, LLC on September 22, 2015 by issuing 2,500,000 shares of Predictive Technology Group, Inc. stock and have no contingencies or royalty obligations. These patents were recorded on Predictive Therapeutics books using the average ten-day trailing market price of the stock, or \$8,095,000.

| Title or Pub # | Ser #, Patent # | | 1st Named Inventor | Status |
|---|-------------------------------|----|--------------------------------------|---------------|
| Apparatus and Method for Dynamic Scoliosis Orthosis | 12/145,959 US 7,967,767 | US | Ogilvie | Issued |
| Method of Treating Scoliosis Using a Biological Implant and Determining Predisposition | 12/341,289 US 8,123,787 | US | Ogilvie | Issued |
| Method of Treating Scoliosis Using a Biological Implant and Determining Predisposition | 13/357,800 US 8,641,738 | US | Ogilvie | Issued |
| Method of Treating Spinal Deformity Using a Biological Implant and Determining Predisposition | 14/170,691 US 2105/0127105 | US | Ogilvie | Issued |
| Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof | 13/364,378 US 2105/0337373 | US | Chettier | Pending |

Additional US and International filings in process

NOTE 5 SUBSIDIARIES AND PORTFOLIO INVESTMENTS

Predictive Therapeutics, LLC

On April 15, 2015, Global Enterprises Group, Inc. (GLHO) announced an agreement to acquire 100% of Predictive Therapeutics, LLC. After the acquisition, GLHO changed its name to Predictive Technology Group, Inc. (the Company). On October 31, 2015, the initial agreement was modified to make certain technical corrections and adjustments for contingencies which were not met at that date. The Company issued a total of 103,065,714 shares in this transaction.

LifeCode Genetics, LLC

On January 26, 2016, the Company announced the acquisition of LifeCode Genetics, Inc. as its wholly owned subsidiary. LifeCode holds a strategic equity investment of 11.885% in Juneau Biosciences, LLC. In addition to the development of an assay and related services for the prognosis and monitoring of endometriosis in the infertility market which the Company has licensed, Juneau is developing technologies for the diagnosis of other women's health issues.

The Company issued common shares to acquire LifeCode, and has recorded the acquisition as a "Portfolio Investment" with an asset valuation of \$16,331,192.

Juneau reports to its members on a calendar year basis and LifeCode records its distributable share of such reported income using the equity method. Juneau does not provide financial information more often than annually.

Predictive Biotech, Inc.

On April 12, 2016, the Company announced the acquisition of ReNovo Biotech, Inc. as its wholly owned subsidiary. The acquisition provides the Company access to ReNovo Biotech's cellular, tissue, biomaterial and regenerative medicine products and product candidates. This subsidiary will be operated under the name Predictive Biotech, Inc. and is recorded as a Portfolio Investment with an asset valuation of \$17,000,000.

The company issued a total of 15,181,870 shares of its common stock for the acquisition of LifeCode Genetics, LLC and Predictive Biotech.

NOTE 6 Variable Interest Entities

FASB Interpretation 46(R), Consolidation of Variable Interest Entities ("FIN 46R") requires the primary beneficiary of a Variable Interest Entity ("VIE") to consolidate the entity and also requires majority and significant variable interest investors to provide certain disclosures. A VIE is an entity in which the equity investors do not have a controlling interest or in which the equity investment at risk is insufficient to finance the entity's activities without receiving financial support from the other parties.

In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, we consider the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and our decision-making role, if any, in those activities that significantly determine the entity's economic performance as compared to other economic interest holders. This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entity's future performance and the exercise of professional judgment in deciding which decision-making rights are most important.

In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, we evaluate all of our economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity's design, including: the entity's capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have the potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of our economic interests is a matter that requires the exercise of professional judgment.

Juneau Biosciences, LLC. The Company has license agreements with Juneau Biosciences, LLC (Juneau) as described in note 4 and has convertible notes receivable in the amount of \$3,043,519 plus accrued interest as described in note 3. If converted, the company would gain approximately 10% ownership of Juneau. Additionally, the Company owns an interest of 11.885% in Juneau through its wholly owned subsidiary, LifeCode Genetics, Inc.

The license agreements with Juneau are limited to specific markets which management estimates to be 25% or less of the total market Juneau intends to seek. Juneau regularly seeks, and has received, investments from private investors and holds debt from other creditors. Juneau's management and board of managers are independent of the Company.

Accordingly, Management has concluded that the Company is not the primary beneficiary of Juneau Bioscience and accordingly, does not hold a significant variable interest in Juneau sufficient to require consolidation (see note 5).

When changes occur to the business relationship of an entity, the Company will reconsider whether it is subject to the VIE model.

NOTE 7 Shareholders Equity

As of March 31, 2017, the Company had 182,884,682 shares issued and outstanding or pending issuance. In addition, options for 650,000 shares have been granted, subject to performance and service period requirements. In addition, there were 2,748,800 warrants outstanding at March 31, 2017 exercisable at \$0.50 through August 1, 2021.

NOTE 8 Commitments and Contingencies

The company has commitments under license agreements which are described in note 4.

NOTE 9 Going Concern

The Company is considered to be in the development stage and through its wholly owned subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic, Tissues and Human Cellular and Tissue-Based Products (HCT/Ps). The financial statements were prepared on a going concern basis. The going concern basis assumes that the company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

NOTE 10 Subsequent Events

Management has evaluated subsequent events through May 12, 2017, the date on which the financial statements were available to be issued.

Management is not aware of any subsequent events that require recognition or disclosure in the financial statements.